G3BP1 modulates SPOP to promote prostate tumorigenesis

Chandrani Mukhopadhyay and Pengbo Zhou

Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY, USA

ABSTRACT

Speckle-type POZ protein (SPOP), a Cullin 3-based ubiquitin ligase (CUL3SPOP), acts as a prostate-specific tumor suppressor. Loss-of-function mutations in SPOP occur in 10% of primary prostate cancer with a high Gleason grade and poor prognosis. However, it is unclear how the ubiquitin ligase activity of SPOP is controlled and how dysregulation of SPOP contributes to malignant transformation. Here, we identified GTPase Activating Protein (SH3 Domain) Binding Protein 1 (G3BP1) as an interactor and upstream regulator of CUL3SPOP, and it functions as an inhibitor of CUL3SPOP ubiquitin ligase, suggesting a distinctive mode of CUL3SPOP inactivation that aggravates prostate cancer.

Dysregulation of Androgen Receptor (AR) signaling is the major pathway associated with prostate cancer (PCa) progression, and agents targeting AR represent the mainstay of pharmacologic therapy for PCa. Speckle-type POZ protein (SPOP) is a tumor suppressor of PCa and functions as a substrate receptor of the Cullin 3 (CUL3)-based ubiquitin ligase.1-4 CUL3SPOP directs ubiquitin-proteasomal degradation of key regulators, e.g., DEK Proto-Oncogene (DEK), Bromodomain Containing 4 (BRD4), Programmed Cell Death Protein 1 (PDI) including AR, and AR co-activators Nuclear Receptor Coactivator 3 (SRC-3) and Tripartite Motif Containing 24 (TRIM24) of the AR signaling pathway. However, the exact mechanisms of SPOP function and regulation in PCa progression remain unclear. Recently, in Nature communications, we have demonstrated a new oncogenic role of stress responsive protein GTPase Activating Protein (SH3 Domain) Binding Protein 1 (G3BP1) that negatively regulates tumor suppressive SPOP ubiquitin ligase, leading to upregulation of AR signaling and prostate tumorigenesis (Figure 1). The study reveals a new way of SPOP inactivation and provides an opportunity for precision intervention against G3BP1high prostate cancer.

To gain a comprehensive understanding of the SPOP signaling network, we conducted proteomic screen (tandem affinity purification and Mass Spectrometry) for SPOP interactors and identified that G3BP1 binds to and interacts with the SPOP-CUL3 complex (CUL3SPOP). To understand the biochemical consequences of G3BP1 and SPOP interaction, we conducted ubiquitination assay where we observed that ectopic expression of G3BP1 reduced CUL3SPOP-dependent ubiquitination of AR, a bona fide SPOP substrate. To further understand the molecular mechanism of G3BP1-mediated SPOP suppression, we performed in vitro ubiquitination assay with affinity-purified recombinant E1, UBCH5 (as E2), CUL3/RBX1, SPOP, and DEK (substrate) and observed that G3BP1 inhibits CUL3SPOP-dependent ubiquitination of DEK in a dose-dependent manner. Moreover, using in vitro binding assay with affinity-purified proteins, we further observed that increasing doses of G3BP1 directly competed with DEK for binding to SPOP, suggesting that G3BP1 functions by excluding SPOP substrates resulting in reduced ubiquitination. Thus, it is conceivable that binding of G3BP1 to CUL3SPOP precludes substrate binding and subsequent transfer of ubiquitin to substrates, resulting in increased accumulation of SPOP substrates (such as AR TRIM24 and SRC3) that aggravate PCa progression (Figure 1).

To evaluate the expression and contributions of G3BP1 in PCa patient tissue, we analyzed TCGA RNA sequencing (RNA-seq) data from 498 patient samples and observed that G3BP1 expression is high in higher prostate cancer Grade Group.8 Next, we evaluated the prognostic impact of G3BP1 by analyzing the tissue microarray (TMA) of 153 independent PCa cases collected at the Weill Cornell Pathology tumor bank. We observed that G3BP1 expression gradually increased in tissue samples of benign to primary PCa tumors and was most abundant in Castration-resistance prostate cancer (CRPC), suggesting that G3BP1 overexpression is associated with more aggressive disease across the clinical spectrum of prostate cancer. Interestingly, when we evaluated the probability of metastasis-free survival of primary 1,626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada),9 we found that patients with “high” G3BP1 expression showed a lesser chance of metastasis-free survival. These findings demonstrated that increased accumulation of G3BP1 correlates with tumor aggressiveness and poor metastasis-free survival.

To provide further insight into G3BP1-mediated deregulation of cellular signaling pathways, we performed RNA-seq of 22RV1 cells after G3BP1 knockout or transient SPOP knockdown and compared them with control cells to identify
changes in transcriptional programs. AR signaling output score was determined using a previously defined AR target gene set,\(^\text{10}\) which was found to be decreased in G3BP1-knockout cells and restored upon SPOP knockdown. This was further validated by RT-qPCR using AR target genes. Altogether, these findings suggest that G3BP1 is an upstream regulator of SPOP, and G3BP1-SPOP ubiquitin signaling axis regulates AR threshold levels and transcriptional program. To validate that G3BP1-SPOP axis mediates AR-driven signaling, G3BP1 was overexpressed in wild type primary mPECs (murine prostate epithelial cells) and AR-KO (AR knock out) mPECs. Here, we observed that G3BP1 overexpression (G3BP1\(^{OE}\)) significantly (p < .001) enhanced organoid formation in WT mPECs, but not AR-KO and AR-KO G3BP1\(^{OE}\) mPECs, which establishes a role for AR in G3BP1-SPOP ubiquitin signaling. To understand the clinical implication, we analyzed three PCA data sets and consistently observed that G3BP1 expression directly correlated with AR signaling both at RNA and protein levels. Moreover, we observed that G3BP1 is a bona fide target of AR that upregulates G3BP1 transcription and sets up a feed-forward loop of AR-mediated adverse signaling that further exacerbates PCa progression. These results provide compelling evidence that AR plays a significant role in G3BP1-SPOP axis-mediated downstream signaling in prostate epithelial cells.

Inspired by the findings that the AR signaling pathway is one of the most deregulated pathways by the G3BP1-SPOP ubiquitin signaling axis, we set to investigate its potential role in prostate cancer pathogenesis. We observed that the G3BP1-SPOP axis regulates invasion potential of 22RV1 human prostate cancer cells. As silencing of G3BP1 was observed to reduce invasion, we sought to investigate the proliferative and tumorigenic potential of G3BP1. Stable G3BP1 knockdown in WT (wild type) mPECs significantly reduced organoid formation. Furthermore, G3BP1 knockout significantly attenuated 22RV1 xenograft tumor formation and growth. Therefore, as demonstrated herein, G3BP1\(^{high}\) constitutes a distinct subclass of prostate cancer. G3BP1 may serve as a new prognostic biomarker in prostate cancer and provide an opportunity for precision therapy of such G3BP1\(^{high}\) patients (Figure 1).

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**ORCID**

Pengbo Zhou [http://orcid.org/0000-0002-4912-2901](http://orcid.org/0000-0002-4912-2901)

**References**

1. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014;6(4):657–669. doi:10.1016/j.celrep.2014.01.013.
2. Furukawa M, He YJ, Borchers C, Xiong Y. Targeting of protein ubiquitination by BTB–Cullin 3–roc1 ubiquitin ligases. Nat Cell Biol. 2003;5(11):1001–1007. doi:10.1038/ncb1056.
3. Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP)
regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci USA. 2013;110(17):6997–7002. doi:10.1073/pnas.1304502110.

4. Xu L, Wei Y, Reboul J, Vaglio P, Shin T-H, Vidal M, Elledge SJ, Harper JW. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature. 2003;425(6955):316–321. doi:10.1038/nature01985.

5. Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato AC, Tschopp P, Gu L, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell. 2016;29(6):846–858. doi:10.1016/j.ccell.2016.04.012.

6. Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346(6205):85–89. doi:10.1126/science.1250255.

7. Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, Deonarine LD, Cyrtta J, Davicioni E, Sboner A, et al. G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. Nat Commun. 2021;12(1):6662. doi:10.1038/s41467-021-27024-x.

8. Egevad L, Delahunt B, Srigley JR, Samaratinga H. International Society of Urological Pathology (ISUP) grading of prostate cancer - an ISUP consensus on contemporary grading. APMIS. 2016;124(6):433–435. doi:10.1111/apm.12533.

9. Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408–412. doi:10.1038/s41586-019-1318-9.

10. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10(4):321–330. doi:10.1016/j.ccr.2006.09.005.